Epoetin Alfa
7 Topics Found
Drug Index
Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology.[3] Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin is manufactured and marketed by Amgen under the trade name Epogen. Johnson & Johnson subsidiary Janssen Biotech (formerly Ortho Biotech Pro...
Drug Index
Darbepoetin alfa (INN) /drbpotn/ is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidne...
Cresp (Vials) is a low-cost version of long-acting anemia drug darbepoetin alfa (Aranesp). Crep Vials Cost USD 175$ for 100 mcg. Darbepoetin is a much longer-acting version of epoetin alfa which is used in the treatment of severe anaemia in chronic kidney conditions and cancer. Cresp is the world’s first generic version of darbepoetin alpha in the world and the only darbepoetin alfa in India (manufactured by Dr Reddy’s) Drug Controller general of India has given approval for Cresp for the treatment of anaemia due to chronic kidney disease and anaemia due to chemotherapy. Darbepoetin alfa is a modified version of epoetin alfa (rHuEPO), which is engineered to have a longer half life, increasing (up to 3 times) the time it remains in the blood. This re...
1 REPLY
Filed under
Aranesp
Epoetin Alfa
Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology.[3] Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin is manufactured and marketed by Amgen under the trade name Epogen. Johnson & Johnson subsidiary Janssen Biotech (formerly Ortho Biotech Pro...
Epoetin Alfa
Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology.[3] Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin is manufactured and marketed by Amgen under the trade name Epogen. Johnson & Johnson subsidiary Janssen Biotech (formerly Ortho Biotech Pro...
Epoetin Alfa-epbx
Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology.[3] Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin is manufactured and marketed by Amgen under the trade name Epogen. Johnson & Johnson subsidiary Janssen Biotech (formerly Ortho Biotech Pro...
Darbepoetin Alfa
Darbepoetin alfa (INN) /drbpotn/ is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidne...